Posts Tagged ‘Vivakor’

Stocks drift lower as investors worry soft retail sales signal spending will remain weak

Stocks drifted lower early Thursday as news of an improving job market failed to offset the market’s disappointment over sales at Wal-Mart Stores Inc.

The Labor Department said new claims for unemployment insurance fell to a seasonally adjusted 502,000 from an upwardly revised 514,000 the previous week. That’s the fewest claims since the week ending Jan. 3, and below economists’ estimates.

The news is evidence the job market is slowly healing.

Read the rest of this entry »

Stocks are slightly lower as investors grow more cautious about the strength of an economic recovery

The market is extending its losses after weakening Tuesday following a disappointing reading on consumer confidence. A new report showing durable goods orders rose in line with expectations in September had little effect on trading.

A disappointing earnings or economic report can give investors a reason to cash in some gains, but overall most signs point toward additional strengthening of the economy and market, Williams added.

Read the rest of this entry »

Stocks plunge on disappointing manufacturing data

A surprise drop in a key regional economic indicator sent stocks reeling in early trading Wednesday, with the Dow Jones industrials tumbling more than 100 points.

The Chicago Purchasing Managers Index fell to 46.1 in September rather than rising to the 52 that economists expected. The index, considered a precursor to the national Institute for Supply Management index to be released on Thursday, pointed to a Midwestern manufacturing sector than is weaker than had been expected.

Read the rest of this entry »

Podcast: Play in new window | Download

Vivakor’s Chairman, Matt Nicosia stopped by SmallCapVoice.com to discuss Vivakor, a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. Vivakor generates revenues through the licensing or sale of its technologies.

CORALVILLE, Iowa–(BUSINESS WIRE)–Vivakor, Inc. (OTCBB: VIVK) today announced that John Gryga, former executive with General Electric’s Healthcare division and former Director of Operations for RadNet, has joined Vivakor’s Board of Directors. At RadNet, Mr. Gryga was responsible for growing annual revenues from $20 million to over $150 million. Mr. Gryga will steer Vivakor in the commercialization of several of its Electro-Optic devices including its VivaSlices MRI image improvement software and its VivaSight vision-screening digital photo-refractor (“DPR”) product, and other medical devices in development at Vivakor.

Read the rest of this entry »

Stocks are sharply higher as investors feel optimistic about corporate takeovers

Stocks are up sharply in the early going Monday after Abbott Laboratories said it would buy the pharmaceutical business of Belgian chemicals maker Solvay for $6.6 billion and Xerox Corp. agreed to acquire Affiliated Computer Services for about $6.4 billion.

The takeover moves are a welcome sign that businesses have enough faith in a recovery in the economy to pursue acquisitions.

A rise was to be expected Monday after the stock market’s latest rally stalled in response to disappointing housing and manufacturing data. Investors are trying to decide whether it’s wise to commit much money to the market while the economic recovery looks more tentative.

Read the rest of this entry »

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. The R&D Core at Vivakor (the idea hub) innovates, develops and validates biomedical devices and biotechnologies. Commercialization of Vivakor technologies is accomplished through partnerships with manufacturers and niche-industry marketing and distribution leaders. Vivakor generates revenues through the licensing or sale of its technologies. Vivakor is preparing a portfolio of intellectual properties and subsidiaries. The subsidiaries will focus on the commercialization of technologies developed by Vivakor.

Read the rest of this entry »

Stocks are mixed amid weaker-than-expected durable goods and housing report

Stocks are mixed in early trading after a weaker-than-expected report on durable goods orders and a report that new home sales edged higher in August but fell short of economists’ expectations touched off new worries about the strength of a recovery in the economy.

Investors were disappointed to hear that durable goods orders unexpectedly fell in August. The second drop in three months shows any rebound in manufacturing is likely to be slow.

Read the rest of this entry »